Nonalcoholic fatty liver disease (NAFLD) embraces histopathological entities ranging from the
relatively benign simple steatosis to the progressive form nonalcoholic steatohepatitis (NASH),
which is associated with fibrosis and an increased risk of progression to cirrhosis and hepatocellur
carcinoma. NAFLD is the most common liver disease and is associated with extrahepatic
comorbidities including a major cardiovascular disease burden.
The non-invasive diagnosis of NAFLD and the identification of subjects at risk of progressive
liver disease and cardio-metabolic complications are key in implementing personalized treatment
schedules and follow-up strategies.
In this review we highlight the potential role of ultrasound semiquantitative scores for detecting
and assessing steatosis severity, progression of NAFLD and cardio-metabolic risk.
Ultrasonographic scores of fatty liver severity act as sensors of cardio-metabolic health and
may assist in selecting patients to submit to second-line non-invasive imaging techniques and/or
Keywords: atherosclerosis, cardiometabolic risk, conventional ultrasound, hepatic fibrosis, hepatic
steatosis, liver biopsy, metabolic derangements
Rights & PermissionsPrintExport